Home Blog Page 359

Mobilize Recovery 2023 Partners With iHeartMedia and Meta to Support Recovery From Addiction and to End Overdose in America

By
NT Editor
-
0
Mobilize Recovery 2023 Partners With iHeartMedia and Meta to Support Recovery From Addiction and to End Overdose in America
Grammy Award-winning artist Macklemore to join the recovery community for Mobilize Recovery 2023 in Washington, D.C.

LAS VEGAS, April 17, 2023 (Newswire.com) - Continuing its mission to support, motivate, and empower the 23 million Americans in long-term recovery, Mobilize Recovery, one of America's largest advocacy groups focused on people seeking and living in recovery from substance use disorder (SUD), is announcing its 2023 campaign and renewed partnerships with iHeartMedia and Meta. Both companies have a longstanding partnership with Mobilize Recovery, helping to promote lifesaving resources while nurturing the recovery community through public awareness campaigns, social media amplification and bold media efforts.

Mobilize Recovery will expand its national media partnerships in 2023 with iHeartRadio and Meta to provide substantial promotional support highlighting the initiative and commitments — including mass market broadcast radio, public service announcements with notable musicians and personalities, and digital promotions throughout September and October. Partners will be included in unique media opportunities both regionally and nationally. In 2022, iHeartMedia and Meta provided mass media support to Mobilize Recovery reaching over 6 million Americans through multiple verticals.

"We are elated and strengthened in our conviction to help those in recovery as our longstanding partners have amplified their commitment in 2023 to make this year the most far reaching, comprehensive, and loudest Mobilize Recovery campaign so far," said Ryan Hampton, co-founder and executive director of Mobilize Recovery. "Through the years, both Meta and iHeartRadio have demonstrated their commitment not just financially - but substantively - in the actions and direct support from their leadership and staff on a very personal level. These are partners that share our vocation to support the recovery community in the most authentic way possible."

Unlike past years when recovery advocacy groups and concerned individuals could attend summits and events by paying for admission, this year's Mobilize Recovery will require attendees to fill out an application due to increased volume of participants and the unbridled growth of the Mobilize Recovery movement (with free admission to those who are accepted to participate). People in recovery, creators in the recovery community, non-profit leaders in the addiction recovery and harm reduction communities, and impacted individuals are all encouraged to apply to attend. The application process opens on Monday, April 17 and can be found at mobilizerecovery.org. While participation and attendance at events in-person will be metered because of space considerations, interested parties will be able to view some of the programming online as well as see some selected archival pieces on video.

Meta continues to bring people together through their platform to provide vital support — whether individuals or loved ones in recovery, health professionals sharing treatment resources or organizations combating the stigma that often prevents people from seeking help. They have supported the work of Mobilize Recovery since its inception in 2019. The organization was initially incubated as a pilot project under the 2019 Facebook Community Leadership Program, a fellowship to support and fund extraordinary community leaders in creating real-world impact.

"Meta is thrilled to continue its participation in this important initiative. We know our platforms are an important place for people in recovery to find resources and support, as well as their families and support systems. Our hope is that 2023 will continue to build on the success of this partnership and impact even more lives," said Avra Siegel, Director of U.S. Policy Programs at Meta.

iHeartMedia, the No. 1 audio company in America, which reaches 90% of Americans every month, is deeply involved with a multi-year engagement supporting Mobilize Recovery and is using its multiple platforms to support community and musical events, as well as a number of PSAs designed to provide local support and resources directly to listeners.

"Mobilize Recovery has become central to iHeart Recovery Month, and this movement is one that drives real and measurable outcomes. As the number one audio company in America by reach, iHeart is in a unique position to help the recovery movement build momentum and support across its industry-leading portfolio of assets and brands," said Alexandra Cameron, Executive Vice President of Unified Partnerships at iHeartMedia. "We have had extraordinary success in reaching communities across America with these important stigma-reducing messages over the last several years, and we're looking forward to working with Mobilize Recovery to build on that success."

Macklemore will join recovery advocates from all 50 states in-person on Tuesday, Sept. 19, in Washington, D.C., on the final day of Mobilize Recovery 2023. Through his participation, the Grammy Award-winning artist will be joining his peers in recovery, committing to inspire recovery and end overdose through various impact projects in local communities across the United States.

To learn more about Mobilize Recovery 2023, or to complete an application for participation, go to mobilizerecovery.org. To view iHeart's activities with Mobilize Recovery in past years, go to iheartrecoverymonth.com.

Contact Information:
Tim Sullivan
Media
[email protected]
(732) 816-0239

Ryan Hampton
Executive Director
[email protected]
(310) 569-3755


Original Source: Mobilize Recovery 2023 Partners With iHeartMedia and Meta to Support Recovery From Addiction and to End Overdose in America

What Happened to Terrence Howard?

By
NT Editor
-
0
What Happened to Terrence Howard?

In the early part of the 2000s, Terrence Howard was on the cusp of major stardom. He’d been around since the mid-nineties, stealing scenes in movies like Dead Presidents, Mr. Holland’s Opus and The Best Man (which spawned a legit franchise). But, it was his role in Paul Haggis’ Oscar-winner Crash that led to many saying he would be the next great actor of his generation. His role in the Sundance break-out Hustle & Flow was a sensation that nabbed him a (well-deserved) Oscar nomination, and he followed it up with excellent character work in Four Brothers, The Brave One, Get Rich or Die Tryin’, and more. But, his role as James Rhodes in Iron Man promised big things to come.

At the time, no one knew the film would kick off the MCU, and he was well-positioned, with his character slated to become War Machine in the sequel. Yet, when Iron Man 2 came out in 2010, he was replaced by Don Cheadle. What happened? The accounts differ, but the consensus is that Howard was asked to take a significant pay cut to continue in the role, and he refused. Since then, Howard has maintained that losing the part harmed his career in a significant way. That said, he went on to arguably his greatest success as an actor in 2015 when he signed on to play the lead in Empire, a TV show that became a cult sensation and made him a household name. But, gossip and Howard’s own bizarre antics seemed to follow him around. Most recently, he was back in the limelight thanks to his continuing role in The Best Man franchise, but following the release of the limited series, The Best Man: The Final Chapters, he announced that he was officially retiring as an actor.

So what happened to Terrence Howard? How does one of the most promising actors of his generation end up virtually retired at only 54? In this episode of What Happened to this Celebrity, which is written (with Mathew Plale), narrated and produced by Taylor James Johnson, and edited by Kier Gomes, we take a look at Howard’s life and legacy. Do you think Terrence Howard is due a comeback and perhaps an apology from Marvel? Let us know in the comments!

Originally published at https://www.joblo.com/what-happened-to-terrence-howard/

Credello: Subprime Credit Holders Are Getting Hit by Rising Interest Rates the Hardest

By
NT Editor
-
0
Credello: Subprime Credit Holders Are Getting Hit by Rising Interest Rates the Hardest

NEW YORK, April 17, 2023 (Newswire.com) - Credello: If you're a subprime credit holder, you could be in for a tough time. Rising interest rates from the Federal Reserve are hitting your score hard, making it harder to get approved for new loans and leading to higher payments. What should you do?

How subprime credit works

What is subprime credit? Subprime credit refers to loans or credit cards given to people with lower credit scores than average. Because these loans are riskier, lenders charge higher interest rates to account for the risk. This makes it harder for subprime borrowers to pay off their debt, and they often default.

Why are interest rates going up?

The Federal Reserve, also referred to as "The Fed," is the central bank in charge of things that affect the US economy, including maintaining the value of the US dollar and curbing inflation. The Fed will adjust interest rates for borrowing money to combat rising inflation. If inflation is low, interest rates will be low to encourage spending to keep the dollar's value high.

If inflation rises, the Fed will raise interest rates to slow down spending so supply levels adjust accordingly.

Because of the economic damage caused by COVID-19, inflation began to rise sharply worldwide. To help the U.S. economy recover, the Fed started raising interest rates. The rising interest rate is a double-edged sword:

If you save money in savings accounts, CDs, etc., then you'll see more money thanks to the increase in interest

If you borrow money via market loans, credit cards, or other methods with variable interest rates, you'll see an increase in your balances because of a higher interest rate charged to your purchases. Adding on the extra costs for goods caused by inflation, and suddenly you're seeing your hard-earned paycheck not covering as much as it used to.

What you can do

There is no guarantee that rising interest rates will cause your credit score to fall, but they could lead to higher payments and decreased access to credit. If this happens, make sure you take action to improve your score.

First, begin working toward turning your subprime score into a prime one. What is a prime credit score? It's a score that's on the other side of the spectrum and is around 660 - 719. People with prime scores tend to have low balances on their credit cards, long histories of on-time payments, and handle their money responsibly. Consequently, they'll see fewer increases in their interest rates and tend to receive more competitive offers for loans and credit cards than those with subprime do.

Unfortunately, credit scores don't fluctuate quickly, but there are a few categories where you should focus your effort to have the most impact:

On-time payments - This is the most significant factor and typically accounts for 35% of your score. Lenders will typically report a late payment if it's over 30 days past due, but this isn't a hard and fast rule. Do your best to make at least the minimum monthly payment on time. The longer your history shows you get what's owed back to a lender on time, the faster your credit score will rise.

The amount of credit you use - If you've had a history of seeing your credit cards as "free money," then you most likely carry balances on your cards. Some were taught this was the way to achieve good credit, but this isn't the case. While it is true that lenders want you to use your cards to make purchases, you're not required to pay interest to raise your score. The highest credit scores utilize no more than 10% of their available credit. 

Other factors that aren't as important are the mix of credit you have, the length of your credit history, and the number of inquiries made on your credit report. While these carry some weight, they're easily canceled out by showing a good history of paying your bills on time and keeping your balances low.

The bottom line

If you're currently dealing with higher interest rates on your credit card or loans, take action to improve your score. You can do several things to raise your chances of getting a better rate, such as improving your credit score and reducing the amount of credit you use.

About Credello

Credello is a financial tech company offering a personal finance tool that simplifies financial decisions through personalized, on-demand recommendations — so users can borrow, save, or invest with confidence. Credello believes that finding the right financial product should be as easy and interactive as online shopping, and we are on a mission to make that possible. For more information, please visit https://www.credello.com. 

Contact Information:
Keyonda Goosby
Public Relations Specialist
[email protected]
(201) 633-2125


Original Source: Credello: Subprime Credit Holders Are Getting Hit by Rising Interest Rates the Hardest

Genome Insight’s Innovative Whole Genome Sequencing Approach to Be Showcased at AACR (American Association of Cancer Research) Annual Meeting 2023

By
NT Editor
-
0
Genome Insight’s Innovative Whole Genome Sequencing Approach to Be Showcased at AACR (American Association of Cancer Research) Annual Meeting 2023

SAN DIEGO, April 17, 2023 (Newswire.com) - Genome Insight, a leading precision medicine and genomics company, announced that their innovative whole genome sequencing (WGS) approach will be featured in six poster presentations at the American Association of Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL. These posters cover a range of topics, including a study of integrative biomarker analysis of regorafenib plus nivolumab (RegoNivo) in hepatocellular carcinoma (HCC), as well as a comparison between whole-genome sequencing-based and targeted panel sequencing approaches to precision oncology.

One notable presentation highlights that Genome Insight's WGS approach provides a more thorough analysis of genetic mutations in breast cancers with homologous recombination deficiency (HRD) than traditional BRCA gene testing. WGS can accurately classify HR status and identify which patients would benefit from polymerase enzymes (PARP) inhibitor treatment, making it a fast and effective screening tool.

"We are thrilled to present our WGS approach at the AACR annual meeting, which demonstrates the potential of our innovative approach to impact clinical decision-making for patients with cancer." - Dr. Young Seok Ju, CEO of Genome Insight

For more information about Genome Insight's WGS approach and other services, visit www.genomeinsight.net.

About Genome Insight 

Genome Insight is a precision medicine whole genome platform company with the goal to accelerate the use of whole genome sequencing (WGS) for accurate diagnosis and personalized treatment for cancer and rare diseases. Genome Insight's proprietary platform is an automated WGS pipeline coupled with a bioinformatics-powered digital solution that rapidly generates meaningful medical insights, making it possible to use WGS in real-life clinical settings. Furthermore, this platform is applied in the research setting to advance novel therapeutic strategies in cancer and rare diseases. The company's headquarters is in San Diego (US) with offices in Korea (Seoul and Daejeon) and Hong Kong. To learn more, please visit www.genomeinsight.net

Contact Information:
Steven Esparza
Chief Executive Officer
[email protected]
6193631368


Original Source: Genome Insight's Innovative Whole Genome Sequencing Approach to Be Showcased at AACR (American Association of Cancer Research) Annual Meeting 2023

Vilcek Foundation Awards $50,000 Prize to Immigrant Biochemist Edward Chouchani

By
NT Editor
-
0
Vilcek Foundation Awards ,000 Prize to Immigrant Biochemist Edward Chouchani
The $50,000 Vilcek Prizes for Creative Promise recognize rising immigrant scientists living and working in the United States whose work represents a significant contribution to their field.


Edward Chouchani receives Vilcek Prize for Creative Promise in Biomedical Science
Harvard Medical School biochemist and cell biologist Edward Chouchani receives $50,000 Vilcek Prize for Creative Promise

NEW YORK, April 17, 2023 (Newswire.com) - Edward Chouchani receives a Vilcek Prize for Creative Promise in Biomedical Science for his work to decipher the molecular mechanisms that drive metabolic disease, with the aim of developing therapeutic interventions. 

The Vilcek Prize for Creative Promise is a $50,000 recognition awarded annually by the Vilcek Foundation as part of its prizes program. Awarded annually since 2006, the Vilcek Foundation prizes recognize and celebrate immigrant contributions to scientific research and discovery, and to artistic and cultural advancement in the United States. The Vilcek Foundation prizes support the Vilcek Foundation's mission to raise public awareness of the value of immigration for a robust society. 

As part of the Vilcek Foundation's recognition of Chouchani's work, the foundation has produced a biographical profile and video profile celebrating his experience and research. Titled "Edward Chouchani seeks to understand the role of metabolism in disease," it is now available on the Vilcek Foundation website.

Born in Canada to an Egyptian academic, Chouchani grew up attending schools in Greece, Thailand, and Cuba as his father's work took the family abroad. This peripatetic lifestyle and a fascination with science fiction literature fostered an innate curiosity in Chouchani about human life and biology. He earned a BS in biochemistry and biotechnology at Carleton University in Ottawa, and his Ph.D. in biological sciences at the University of Cambridge. In 2014, he moved to Boston to pursue postdoctoral research at Harvard Medical School, where he is now an associate professor of cell biology. Chouchani directs a research laboratory at the Dana-Farber Cancer Institute, where he is also an associate professor of cancer biology. 

"Edward Chouchani's research has had a powerful impact on our current understanding of metabolism and mitochondrial biology," says Vilcek Foundation Chairman and CEO Jan Vilcek. "His approach encompasses the spectrum of research, from bench science to computational analysis. With this approach, he has not only developed new tools and methods to study metabolism in cells, but has identified potential clinical applications and interventions for metabolic and metastatic disorders and disease."

Chouchani's work primarily focuses on metabolism, using mass spectrometry and biochemical approaches to understand how metabolites regulate cellular function in pre-clinical models of health and disease. The research implications are myriad: By better understanding the function of metabolism and the role that different metabolites play in living cells and tissues, Chouchani and his team can identify metabolites and enzymes that contribute to disease.

"Mass spectrometry lets us peer into the cell and systematically map how metabolism controls our biology," he says. "Our goal is to leverage these newfound mechanisms to develop new therapies for metabolic, inflammatory, and metastatic diseases."

"There are over 20,000 different types of protein machines in the cell and over 95% of them are what's called un-drugged," he says. "The way our technology works, we query many of those 20,000 proteins in living systems and look for pockets where small-molecule metabolites can interact with them." By finding and understanding these pockets, Chouchani and his team illuminate metabolic functions and identify potential points of intervention. "If we can understand the nooks and crannies of where these interactions occur, we can develop new ways to leverage these interactions, and protect against cancers and diseases of aging."

Chouchani is energized by his work, and takes inspiration from his research team and colleagues at Harvard. "That really is one of the most invigorating things about science," he says. "If you're doing it properly, and with the right people, it starts evolving in ways you never could have anticipated, and it makes it one of the most exciting careers that one can have."

Access the full article and video at the Vilcek Foundation: Edward Chouchani seeks to understand the role of metabolism in disease

Contact Information:
Elizabeth Boylan
Communications Manager
[email protected]
+12124722500
Related Files
2023VFP - Press Release - Edward Chouchani - Newswire.pdf



Original Source: Vilcek Foundation Awards $50,000 Prize to Immigrant Biochemist Edward Chouchani

Heather Elias to Lead Pearl Certification’s Real Estate Division

By
NT Editor
-
0
Heather Elias to Lead Pearl Certification’s Real Estate Division

Heather Elias, Pearl Certification
Heather Elias, long-time REALTOR and broker, joins Pearl Certification as its new Vice President of the Real Estate Division.

CHARLOTTESVILLE, Va., April 17, 2023 (Newswire.com) - Pearl Certification, the industry's foremost third-party certification program for high-performing homes, announces that Heather Elias, a real estate and marketing expert, will lead the company's Real Estate Division as its new Vice President.

"I'm thrilled to join a purpose-centered company that is striving to transform the national housing market for good," said Elias. "The 'north star' of my nearly two decades of work in real estate has been to do everything I could to improve the industry, and this role gives me a unique opportunity to have a massive impact." 

As a true pioneer of the real estate industry's digital era, Elias was one of the first real estate agents in the U.S. to leverage digital marketing to build a business by blogging about her local area when she became a REALTOR® 19 years ago.

Prior to joining Pearl, Elias served as CEO of Artisan Consulting, advising numerous proptech companies as they expanded into the real estate industry. Her work included building and launching a national, referral-only real estate brokerage, creating and managing influencer/advocate programs, and developing recruiting and brand strategies for brokerages.

Elias's prior roles also included overseeing the social and digital strategy for the National Association of REALTORS® as its Director of Social Business Practice and championing the brand story for Century 21 Redwood Realty, leading the brokerage's expansion to 12 offices and nearly 500 agents.

"Pearl is delighted to welcome Heather to a key role in Pearl's leadership team," said Robin LeBaron, co-founder and president of Pearl Certification. "She has an exceptionally broad and deep knowledge of the real estate industry, with experience that spans marketing and branding, policy, proptech, and on-the-ground work as a salesperson. Heather's leadership will be crucial to ensuring that Pearl continues to realize its brand promise — that energy-efficient, high-performing homes are properly valued at time of sale." 

To learn more about bringing knowledge of high-performing homes to the real estate industry or to join the Pearl Network, please visit pearlcertification.com/real-estate-pros/.

About Pearl: Pearl Certification is the gold standard in high-performing home certifications, bringing visibility to the valuable features that make them healthy, safe, comfortable, and energy- and water-efficient. Pearl is the only national sponsor of the U.S. Department of Energy's Home Performance with ENERGY STAR® program and is a partner with the National Association of REALTORS® Green Resource Council. Pearl has certified and provided appraisal addenda on over 132,000 homes in 44 states and Washington, D.C. Pearl Certified homes sell on average for 5.5% more than comparable homes, according to independent appraiser studies. https://pearlcertification.com/

Contact Information:
Caprice Johnson
Marketing Manager, Real Estate Division
[email protected]
(646) 463-2826


Original Source: Heather Elias to Lead Pearl Certification's Real Estate Division

Landmark Report Captures Compelling Testimony by Families and Caregivers About Living with SYNGAP1-related Disorders and Urgent Need for Treatments

By
NT Editor
-
0
Landmark Report Captures Compelling Testimony by Families and Caregivers About Living with SYNGAP1-related Disorders and Urgent Need for Treatments
The SYNGAP1 Gene: Seeking Treatments and the Genetic Link to Related Neurological Disorders

WASHINGTON, April 17, 2023 (Newswire.com) - The SYNGAP1 Foundation has released its SYNGAP1: Voice of the Patient and Caregiver Report, a landmark publication based on its Nov. 19, 2020, externally led patient-focused drug development (EL-PFDD) meeting. Families and caregivers living with SYNGAP1 participated via Zoom, email, and calling in, sharing stories and input captured in the Voice of the Patient Report. It will provide the FDA and the biopharmaceutical industry with deep insights into how SYNGAP1-related disorders affect individuals' health, daily lives, and well-being. Individuals and families living with SYNGAP1-related conditions shared with U.S. Food and Drug Administration (FDA) representatives and other stakeholders about how the neurodevelopmental disorder affects symptoms and hopes for future treatments to improve quality of life. 

The SYNGAP1 gene provides instructions for making a protein called SynGAP, which plays an essential role in nerve cells in the brain. SYNGAP1 mutations' prevalence is 2%-4% of sporadic (non-Inherited) cases of intellectual disability worldwide. Five out of 500 persons diagnosed with epileptic encephalopathy have a SYNGAP1 mutation. The frequency of these mutations is like that of Fragile X Syndrome, the most common inherited cause of Intellectual Disability ("ID worldwide"). Gene Reviews 

The report describes the array of clinical symptoms suffered by individuals with SYNGAP1 mutations, a few being the most common, such as developmental delay, intellectual disability, epilepsies, speech delay, impaired communication, and sensory processing disorder. One individual explained a few of her symptoms living with SYNGAP1, "I'm obsessed with making lists and organizing, and I have sensory issues related to noise and certain textures." Another mother described her concern for her toddler: "He didn't take his first steps until he was almost two, and shortly before his second birthday, he began walking independently. His gross motor skills were delayed, and he had trouble doing simple tasks, such as feeding himself." The average age for walking is 26 months (range: 10.5 months to 5 years). Language is generally impaired; a third of individuals aged five years or more remain nonverbal. In those who are verbal, language development ranges from the use of single words only to four-to-five-word sentences. 

In addition, other symptoms observed in patients include inattention, impulsivity, self-directed and other-directed aggressive behavior, elevated pain threshold, hyperacusis, and sleep disorders, which also include autism spectrum disorders (ASD). Autism diagnosis may be as high as 50% of SYNGAP1 patients, including stereotypic behaviors such as hand flapping, obsessions with objects, and poor social development. 

Short of a cure, families consistently stated that the top three symptoms as the target of a new therapy would be the ability to control seizures, improved behavioral control, and improved ability to communicate. Many people also indicated help with motor skills and self-care, halting disease progression, improved social interactions, and improved cognitive ability. Being understood is a top desire of caregivers and families. The common theme in comments shared during the meeting is that families and caregivers living with SYNGAP1-related disorders are willing to tolerate a higher degree of uncertainty about the effectiveness of a new drug, given the dire, unmet need they currently experience. A mother of a child expressed, "I hope that something comes out to target the root of the problem, which will alleviate many of the symptoms. We desperately need something, because the side effects often outweigh the benefits of many meds." Another testified, "Since this is so incapacitating, even invasive therapy delivery procedures will be welcome."

Contact Information:
Monica Dudley-Weldon
President & Founder, SYNGAP1 Foundation
[email protected]
2403470302

Matt Toresco
Chief Operations Officer/ SYNGAP1 Foundation
[email protected]


Original Source: Landmark Report Captures Compelling Testimony by Families and Caregivers About Living with SYNGAP1-related Disorders and Urgent Need for Treatments

ADHD Online Leaders Address Hidden Issue of Entrepreneurs’ Common Mental Health Challenges

By
NT Editor
-
0
ADHD Online Leaders Address Hidden Issue of Entrepreneurs’ Common Mental Health Challenges
CEO Zach Booker also praises Midwest as haven for startups

GRAND RAPIDS, Mich., April 17, 2023 (Newswire.com) - In two events at the recent SXSW Conference, ADHD Online, the leader in online ADHD testing and assessment, outlined the reasons for its exponential growth and addressed the unspoken prevalence of mental health issues for entrepreneurs.

"ADHD Online is based in Grand Rapids, Michigan, far from the entrepreneurial hotbeds of the U.S. coasts. But the Midwest is a powerhouse of talent, with unique opportunities, and ADHD Online leveraged the region's advantages," CEO Zach Booker told the crowd at the "Scaling in the Midwest" panel. "That allowed the company to grow to serve patients in all 50 states in just one year," Booker said.  

"Central to that success was the company's philosophy and structure, which allowed it to 'plug and play' a system that delivers and maintains a high standard of care for treating mental health patients in the same way regardless of where they live," Booker said.  

At the "Mental Health and Entrepreneurs" panel, Keith Brophy, ADHD Online's chief operating officer, outlined the increasing prevalence of mental health issues in the United States and among entrepreneurs in particular. According to the Centers for Disease Control, one in five Americans will experience a mental illness in a given year, while one in 25 lives with a serious mental illness.  

"Among the factors that can contribute to mental illness are adverse life experiences, substance abuse, trauma, loneliness and isolation - with the latter two being common problems among entrepreneurs as they create and launch their ventures," Brophy said, citing a number of studies. 

Entrepreneur Online reports found that one in four entrepreneurs will experience mental illness of some kind, with anxiety and depression the most common issues. A recent study found that 72% of entrepreneurs had mental health problems. And statistics from the National Institute for Mental Health show that entrepreneurs have depression at twice the rate of the general population, six times the rate of ADHD, three times the rate of bipolar disorder, and twice the rate of addiction. 

"Our panel really set the stage for entrepreneurs to be open in discussing their mental health and not hiding behind the mystique of entrepreneurs and leaders, where they can't be authentic about their mental health," Brophy said.  

"The mental health of entrepreneurs is overlooked, or even swept under the rug," Booker agreed. "There's an assumption that people have that entrepreneurs must be good at everything since they're in business for themselves. And the 'fake it until you make it' phenomenon means many entrepreneurs can't be honest about their struggles." 

To learn more about ADHD Online and Mentavi Health, visit https://adhdonline.com/. 

About ADHD Online

ADHD Online was founded in 2018 with the mission that everyone should have access to quality ADHD assessments regardless of who and where they are. The ADHD Online team is filled with industry experts across the United States who all share the same passion for ADHD and making sure patients have access to critical mental health services. ADHD Online is leading the way with being a critical voice for those who might be struggling with ADHD and is the only organization to offer HIPAA-secured ADHD assessments online with results from licensed psychologists. ADHD Online is active in all 50 states.

Contact Information:
Mike Albanese
[email protected]


Original Source: ADHD Online Leaders Address Hidden Issue of Entrepreneurs' Common Mental Health Challenges

Dead Hot trailer: Vanessa Hudgens explores witchcraft and ghost hunting in unscripted Tubi film

By
NT Editor
-
0
Dead Hot trailer: Vanessa Hudgens explores witchcraft and ghost hunting in unscripted Tubi film

Tubi has unveiled a trailer for the unscripted film Dead Hot, about Vanessa Hudgens’ exploration of witchcraft. Now streaming for free

A couple months ago, we heard that the free streaming service Tubi had picked up the streaming rights to the unscripted film Dead Hot, starring Vanessa Hudgens (who recently signed on for Bad Boys 4) and her best friend, musician GG Magree. Dead Hot has been released through Tubi today, and you can check out the trailer in the embed above to see what it’s all about.

Described as “an intimate journey into the supernatural realm that explores identity, feminine power and sisterhood”, Dead Hot has the following synopsis: Hudgens and Magree are self-taught students of witchcraft and have been experimenting and connecting with the spirit world for much of their lives. But after a ghost hunt gone wrong, the duo realizes they need to seek out proper mentorship and training, so they head on a pilgrimage to Salem with cameras chronicling their journey for a masterclass in witchcraft. 

The film comes to us from Bunim-Murray Productions and Banijay Rights. Bunim-Murray’s president Julie Pizzi told Variety that Dead Hot was originally supposed to focus on ghost hunting, an element that is still quite prominent in the trailer, but became something more like a spiritual coming-of-age story. Hudgens said the project “was developed and created out of pure passion”.

Tubi’s Adam Lewinson added, “Dead Hot is a uniquely authentic exploration of spirituality and female empowerment. This personal and powerful journey through the supernatural with Vanessa Hudgens and GG Magree will deeply engage Tubi viewers with premium storytelling from our partners at Bunim-Murray and Banijay.“

Variety noted that, “Witchcraft is not just an interest of Hudgens and Magree. Dead Hot taps into a recent fascination with witchcraft — at least across social media, with the hashtag #WitchTok garnering over 36 billion views on TikTok.“ That quote is just a couple months old, but the #WitchTok view count has already surpassed 40 billion since then.

What did you think of the Dead Hot trailer? Will you be watching Hudgens’ and Magree’s exploration of witchcraft and ghost hunting now that it’s streaming for free on Tubi? Let us know by leaving a comment below.

Originally published at https://www.joblo.com/dead-hot-trailer-vanessa-hudgens-tubi/

HanchorBio Announces US IND Clearance for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies

By
NT Editor
-
0
HanchorBio Announces US IND Clearance for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies
HanchorBio Received IND Clearance of HCB101 Multi-regional Clinical Trial By US FDA


HanchorBio_logo
HanchorBio company logo

TAIPEI, Taiwan & SAN FRANCISCO, April 17, 2023 (Newswire.com) - HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the US. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma.

Scott Liu, Ph.D., Founder, Chairman, and Chief Executive Officer of HanchorBio, commented, "Although there is demonstrated history of PD-1/PD-L1 immune checkpoint inhibitors showcasing strong efficacy in a variety of cancers and significantly improved the prognosis of certain cancer patients, there is a large percentage of cancer patients who are either refractory to these immunotherapies or develop resistance. HCB101 is our independently-developed leading candidate to block the "do not eat" signal from the SIRPα-CD47 pathway, sufficiently eliminating tumor cells by macrophage while exhibiting excellent safety profile in our preclinical studies. The FDA clearance of our first IND marks a significant milestone for HanchorBio and demonstrates our team's continuous focus and commitment to bringing novel immunotherapies to patients with significant unmet need."

"Based on our studies in 15 murine xenograft tumor models of solid and hematological malignancies, HCB101 has demonstrated superior anti-tumor efficacy, both as monotherapy and in combination with other agents. The advantage is even more apparent when comparing HCB101 with other agents targeting the same pathway currently being investigated in clinical trials," said Sean Juo, Ph.D., President and Chief Scientific Officer of HanchorBio. "Unlike other CD47-blocking agents, HCB101 exhibits excellent safety profiles in the repeat-dose cynomolgus monkey toxicology studies, as no abnormality of RBC or platelet levels were observed. It is an important safety factor for differentiation. I look forward to advancing the clinical development of HCB101 and continuing the focus on patient-centric research and development to hopefully bring novel treatments with clinically meaningful benefits to patients as early as possible."

About HCB101

Using structure-guided protein design and engineering supplemented with relevant screening technologies, HCB101 is an engineered extracellular domain of SIRPα fused to the Fc region of IgG4. HCB101 triggers phagocytic activity of the macrophages by blocking the "do not eat" signal between macrophages and tumor cells. Based on the extensive in-vitro and in-vivo preclinical data, HCB101 is potentially a safer and more potent biologic than the anti-CD47 monoclonal antibodies and SIRPα fusion proteins currently being investigated in clinical trials. Furthermore, quantitative RNA transcriptional analysis indicated that HCB101 triggered distinct gene expression profiles inside the tumor and in the tumor microenvironment comparing to other relevant clinical candidates, suggesting that HCB101 might exhibit unique mechanisms of action.

About Multi-Regional Clinical Trial of HCB101

HCB101-101 is a multi-regional, multi-center, open-label, dose-finding, first-in-human (FIH) study of adults with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma in the United States and Taiwan. The purposes of the study are to evaluate the safety, tolerability, pharmacokinetics, and clinical anti-tumor activity of weekly HCB101 intravenous injections. The HCB101 IND is on track being reviewed by the Taiwan FDA.

About HanchorBio 

Based in Taipei, Shanghai, and San Francisco Bay Area, HanchorBio is a global clinical-stage biotechnology company focusing on immuno-oncology. The Company is led by an experienced team of pharmaceutical industry veterans with proven track-record of success in biologics discovery and global development to transcend current cancer therapies. Committed to reactivating the immune system to fight against diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables unique biologics with diverse multi-targeting modalities to unleash both innate and adaptive immunity to overcome the current challenges of anti-PD1/L1 immunotherapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing process in CMC, HanchorBio develops transformative medicines to address unmet medical needs. 

For more information, please visit: www.HanchorBio.com

or follow us on LinkedIn at www.linkedin.com/company/hanchorbio-inc

Contact Information:
Scott Liu
Founder, Chairman and CEO
[email protected]

Yi Du
Sr. Director of Business Development
[email protected]


Original Source: HanchorBio Announces US IND Clearance for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies
1...358359360...579Page 359 of 579
© Newsmag WordPress Theme by TagDiv